David Wechsler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
David Wechsler has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anne Lee
Department of Ophthalmology, Sydney Eye Hospital, Sydney, Australia
2 shared publications - Brandon Huynh
Department of Ophthalmology, Sydney Eye Hospital, Sydney, Australia
2 shared publications - Colin Clement
The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia
2 shared publications Getiye Kibret
Macquarie University, Sydney, Australia
2 shared publications- Mitchell Lawlor
The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia
2 shared publications - Ridia Lim
Department of Ophthalmology, Sydney Eye Hospital, Sydney, Australia
2 shared publications
Latest Publications
- Open Access
- 10 December 2024
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-2
Correction: Outcomes of iStent inject combined with cataract surgery in Asian eyes: Australian data from the Fight Glaucoma Blindness international registry
- 10 December 2024
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-2
Open AccessCorrection: Outcomes of iStent inject combined with cataract surgery in Asian eyes: Australian data from the Fight Glaucoma Blindness international registry
- Open Access
- 25 April 2024
- Published by Springer Nature in International Ophthalmology
- Vol. 44 (1) , 1-9
Outcomes of iStent inject combined with cataract surgery in Asian eyes: Australian data from the Fight Glaucoma Blindness international registry
Purpose To analyse real-world outcomes in Asian eyes of iStent inject, a second-generation trabecular micro-bypass stent, combined with phacoemulsification. Methods This is a multi-centre, observational study of glaucomatous Asian eyes that have undergone iStent inject implantation combined with cataract surgery. Patient data were extracted from the Fight Glaucoma Blindness! Registry. Outcome measures included those of IOP reduction, glaucoma medication reduction, and adverse events including the need for secondary surgery. Results 123 eyes of 86 patients with a mean age of 68.4 ± 9.3 years underwent iStent inject implantation with phacoemulsification. At baseline, the mean ± SD preoperative intraocular pressure (IOP) was 16.0 ± 4.4 mmHg, and the mean preoperative number of topical glaucoma medications was 1.9 ± 1.4. At 12 months 30.8% of eyes demonstrated a reduction in IOP greater than 20%, the mean IOP reduction was 12.5% with an additional reduction of 0.7 glaucoma medications. 40% of eyes were using no medications at 12 months compared to 16.3% preoperatively. 8.2% of eyes required a subsequent procedure within the 12-month follow-up window. Conclusion iStent inject implantation combined with phacoemulsification in Asian eyes showed a reduction of IOP and glaucoma medication use in a real-world clinical setting. The safety profile of the device is good with minimal adverse outcomes, however, a subset of patients required secondary procedures within the 12 month follow up.
- 25 April 2024
- Published by Springer Nature in International Ophthalmology
- Vol. 44 (1) , 1-9
Open AccessOutcomes of iStent inject combined with cataract surgery in Asian eyes: Australian data from the Fight Glaucoma Blindness international registry
Purpose To analyse real-world outcomes in Asian eyes of iStent inject, a second-generation trabecular micro-bypass stent, combined with phacoemulsification. Methods This is a multi-centre, observational study of glaucomatous Asian eyes that have undergone iStent inject implantation combined with cataract surgery. Patient data were extracted from the Fight Glaucoma Blindness! Registry. Outcome measures included those of IOP reduction, glaucoma medication reduction, and adverse events including the need for secondary surgery. Results 123 eyes of 86 patients with a mean age of 68.4 ± 9.3 years underwent iStent inject implantation with phacoemulsification. At baseline, the mean ± SD preoperative intraocular pressure (IOP) was 16.0 ± 4.4 mmHg, and the mean preoperative number of topical glaucoma medications was 1.9 ± 1.4. At 12 months 30.8% of eyes demonstrated a reduction in IOP greater than 20%, the mean IOP reduction was 12.5% with an additional reduction of 0.7 glaucoma medications. 40% of eyes were using no medications at 12 months compared to 16.3% preoperatively. 8.2% of eyes required a subsequent procedure within the 12-month follow-up window. Conclusion iStent inject implantation combined with phacoemulsification in Asian eyes showed a reduction of IOP and glaucoma medication use in a real-world clinical setting. The safety profile of the device is good with minimal adverse outcomes, however, a subset of patients required secondary procedures within the 12 month follow up.